SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-026871
Filing Date
2024-03-28
Accepted
2024-03-28 07:01:29
Documents
15
Period of Report
2024-03-28
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0202743-8k_aldey.htm   iXBRL 8-K 27291
2 ALDEYRA THERAPEUTICS, INC. PRESS RELEASE DATED MARCH 28, 2024 ea0202743ex99-1_aldey.htm EX-99.1 16509
3 GRAPHIC image_001.gif GRAPHIC 3952
  Complete submission text file 0001213900-24-026871.txt   233900

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE aldx-20240328.xsd EX-101.SCH 3057
5 XBRL LABEL FILE aldx-20240328_lab.xml EX-101.LAB 34916
6 XBRL PRESENTATION FILE aldx-20240328_pre.xml EX-101.PRE 22817
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0202743-8k_aldey_htm.xml XML 3782
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 24793445
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)